Video | Agriculture | Confidence | Economy | Energy | Employment | Finance | Media | Property | RBNZ | Science | SOEs | Tax | Technology | Telecoms | Tourism | Transport | Search

 


Tender for generic medicines contributes $38 million savings

PHARMAC tender for generic medicines contributes $38 million savings


New Zealanders’ use of generic medicines is likely to grow further following the just-completed 2013/14 PHARMAC tender. The tender reached record levels this year, receiving nearly 3500 offers to supply pharmaceuticals from 54 companies.

PHARMAC has now awarded 246 contracts from this tender process, likely to produce savings of approximately $38 million (across hospital and community medicines) over three years.

“The savings from the tender are important for PHARMAC and serve two purposes,” says PHARMAC’s Director of Operations Sarah Fitt. “Firstly we need to make savings to enable us to fund the growing volume of medicine that is used in New Zealand each year.”

“And secondly, it can free up funding that we can then use to invest in new medicines. This enables us to produce greater health gains for New Zealanders, which is what PHARMAC is all about.”

New Zealand already has one of the highest usage rates of generic medicines in the world, according to the OECD Health at a Glance report1 The report shows over 73 percent of medicines used in New Zealand are generics. Only Germany and the UK have higher rates of generics use.

Sarah Fitt says this comparatively high usage in New Zealand is largely because of the annual PHARMAC tender, which actively seeks bids for medicines coming off-patent and promotes competition between suppliers.

“New Zealanders are now familiar with generic medicines, and are used to changing between brands of medicine from time to time,” says Sarah Fitt. “This can happen as a result of our tender, and PHARMAC supports change through information for patients, pharmacists and prescribers. This has also helped with acceptance of generics.”

Sarah Fitt says people also have greater understanding that generic medicines go through the same quality, safety and efficacy checks as any other medicine before being registered by Medsafe.

PHARMAC also actively manages all supply contracts to ensure New Zealand continues to enjoy fewer stock shortages than other countries.

Significant decisions from the current tender include new contracts for different presentations of the painkiller paracetamol, New Zealand’s most-prescribed medicine, which is estimated to result in saving more than $2 million over three years.

Moving to sole supply of the mental health medicines, quetiapine and olanzapine will produce the biggest savings from the current tender so far. The quetiapine decision – moving to the Quetapel brand – is likely to save more than $6 million over three years. And sole supply for olanzapine adds a further $2 million of savings. There’s information about these changes at http://www.pharmac.health.nz/medicines/my-medicine-has-changed/antipsychotic-medicines/.

1 http://www.oecd.org/els/health-systems/Health-at-a-Glance-2013.pdf

Other products awarded tenders that will produce savings of $1 million or more over three years include the painkiller tramadol, the cancer treatment paclitaxel, and the migraine medicine rizatriptan.

ENDS

© Scoop Media

 
 
 
 
 
Business Headlines | Sci-Tech Headlines

 

Post-Post: Brian Roche To Step Down As NZ Post CEO

Brian Roche will step down as chief executive of New Zealand Post in April 2017, having led the state-owned postal service's drive to adjust to shrinking mail volumes with a combination of cost cuts, asset sales, modernisation and expansion of new businesses. More>>

ALSO:

Company Results: Air NZ Rides The Tourism Boom With Record Full-Year Earnings

Air New Zealand has ridden the tourism boom and staved off increased competition to deliver the best full-year earnings in its 76-year history. More>>

ALSO:

New PGP: Sheep Milk Industry Gets $12.6M Crown Funding

The Sheep - Horizon Three programme aims to develop "a market driven, end-to-end value chain generating annual revenues of between $200 million and $700 million by 2030," according to a joint statement. More>>

ALSO:

Half Full: Fonterra Raises Forecast Milk Price

Fonterra Co-operative Group Limited today increased its 2016/17 forecast Farmgate Milk Price by 50 cents to $4.75 per kgMS. When combined with the forecast earnings per share range for the 2017 financial year of 50 to 60 cents, the total payout available to farmers in the current season is forecast to be $5.25 to $5.35 before retentions. More>>

ALSO:

Keep Digging: Seabed Ironsands Miner TransTasman Tries Again

The first company to attempt to gain a resource consent to mine ironsands from the ocean floor in New Zealand's Exclusive Economic Zone has lodged a new application containing fresh scientific and other evidence it hopes will persuade regulators after their initial application was turned down in 2014. More>>

Wool Pulled: Duvets Sold As ‘Premium Alpaca’ Mostly Sheep’s Wool

Rotorua business Budge Collection Limited (Budge) and sole director, Sun Dong Kim, were convicted and fined a total of $71,250 in Auckland District Court after each pleading guilty to four charges of misrepresenting how much alpaca fibre was in their duvets. More>>

Get More From Scoop

 
 
 
 
 
 
 
 
 
Business
Search Scoop  
 
 
Powered by Vodafone
NZ independent news